Ecuador Decreto Ejecutivo 1290: ARCSA Creation and Regulatory Powers

Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

ARCSA was established in 2012 under Decreto Ejecutivo 1290, carved out of the former National Institute of Hygiene and Tropical Medicine (INH, Dr. Leopoldo Izquieta Perez), and was amended in 2015 by Decreto Ejecutivo 544. Its authority to issue technical regulations for medical devices flows directly from Article 10 of that decree, which is the legal foundation allowing ARCSA to reshape the registration system at high frequency through resolutions. Understanding this decree therefore explains both where ARCSA jurisdiction begins and why the Ecuadorian rulebook changes so often without any legislative procedure.

2. Legal basis

Regulation	Reference number	Publication date	Articles
Decreto Ejecutivo 1290	Registro Oficial Suplemento 788	2012-09-13	Article 9 (scope of regulated products and establishments), Article 10 (powers and responsibilities)
Decreto Ejecutivo 544 (amending Decreto 1290)	Registro Oficial 428 (signed 2015-01-14)	2015-01-30	Amending articles
Substitute Technical Health Regulation for the Health Registration, Control and Surveillance of Medical Devices for Human Use	Resolucion ARCSA-DE-2026-003-DASP	Signed 2026-04-28	Cited in the preamble
Ley Organica de Salud	Ley 67/2006, Registro Oficial Suplemento 423	2006-12-22	Article 132

3. Expert insights

Insight one: the institute name embedded in the official title is both a matter of institutional history and an authenticity anchor. The formal full name of ARCSA is Agencia Nacional de Regulacion, Control y Vigilancia Sanitaria – ARCSA, Doctor Leopoldo Izquieta Perez, retaining the name of the former National Institute of Hygiene and Tropical Medicine. Official resolutions must carry the complete institutional name in their signature block; any omission is an anomaly.

Insight two: Decreto Ejecutivo 1290 also did something else at the same time, namely splitting out INSPI. The text cited in the preamble of the new regulation shows that the decree separated the former National Institute of Hygiene and Tropical Medicine and created two institutions, the National Institute of Public Health Research (INSPI) and ARCSA. This explains why INSPI overlaps with ARCSA in the fields of in vitro diagnostics and public health.

Insight three: Article 10 is the root of the low-tier, high-frequency amendment pattern. That article delegates directly to ARCSA the power to issue technical regulations, standards and procedures, so major changes to the registration system, such as the 2026 new regulation, require only a resolution signed by the ARCSA Executive Director, with no need to pass through the National Assembly or ministerial-level procedures. This explains the dense succession of resolutions between 2016 and 2026: 026-2016, 004-2017, 033-2017, 030-2018, 2023-001, 2023-033 and 2026-003.

Insight four: the dual-track jurisdiction over products and establishments drawn by Article 9 is the key to the structure of the whole regulation. Articles 5 to 59 of the new regulation govern products (registration, changes, renewal and labeling), Articles 60 to 63 govern establishments (operating permits, good manufacturing practices and ISO 13485 registration), and Articles 64 to 72 govern post-market surveillance and liability. This structure maps directly onto the jurisdictional division in Article 9.

Insight five: the 2015 amendment did not change the core powers. The preamble of the new regulation cites both Decreto 1290 and Decreto 544, confirming that the current basis of ARCSA authority is Decreto Ejecutivo 1290 as amended by Decreto Ejecutivo 544.

4. Practical recommendations

Verify the full institutional name when authenticating ARCSA documents: the complete name must include Doctor Leopoldo Izquieta Perez.
Track regulatory change through ARCSA resolutions as the primary channel, without waiting for legislative-level amendments.
Build the compliance ledger around the dual-track jurisdiction of Article 9: keep product files and establishment files separately managed.
Cite the authority basis precisely in legal documents as Article 10 of Decreto Ejecutivo 1290 as amended by Decreto Ejecutivo 544, raising the rigor of submissions.
Search the registration database by registration number; the historical names of the agency do not affect the validity of existing certificates.

5. Verification checklist

□ Every ARCSA document in use has been confirmed as the version published in the official gazette
□ The full institutional name in the signature block has been checked for completeness
□ The current authority basis has been confirmed as Decreto Ejecutivo 1290 as amended by Decreto 544
□ Compliance files have been organized on the product and establishment dual tracks
□ The complete list of predecessor regulations cited in the preamble of the new regulation has been archived
□ Regulatory tracking has been assigned to a named owner with a periodic review cycle

Regulatory information verified as of October 29, 2026

GRZAN core service lines

Global registration access: EU CE (MDR/IVDR), US FDA (510(k)/De Novo/PMA), UK UKCA, Australia TGA, Canada Health Canada, Brazil ANVISA and Russia RZN, together with pre-market registration pathway planning and submission execution across Latin America, Southeast Asia and the Middle East.
Authorized representative services: EU EC REP, UK RP, Swiss CH REP, Australian sponsor and US Agent holding and representation services, with support for neutral license-holder structures.
Quality system compliance: ISO 13485 establishment and maintenance, MDSAP audit preparation, GMP conformity coaching, and technical documentation (TD) drafting and remediation.
Clinical and evaluation support: clinical evaluation plans (CEP) and reports (CER), equivalence argumentation, PMCF planning and execution, and IVD performance evaluation.
Post-market compliance: vigilance and adverse event reporting, FSCA and recall execution, registration change and renewal management, and maintenance of national regulatory databases.

Why manufacturers choose GRZAN

Local regulatory teams: target-market work is performed by locally licensed regulatory professionals, and submission dossiers are written directly in the local official language without secondary translation.
Neutral license-holder structures: GRZAN offers holding arrangements that are not tied to any distribution channel, preventing registration certificates from being locked in by channel partners.
Regional leverage: one technical dossier can be reused across Andean Community and Mercosur member states, spreading regional compliance costs.
Full lifecycle support: from classification determination and pathway design through dossier preparation, license holding, customs clearance, post-market vigilance and renewal.

Contact

GRZAN provides registration support in Ecuador for manufacturers, importers and authorized representatives.
Email: info@grzanglobal.com
Service inquiries: Ecuador and Andean market registration plans, license-holder structure design, official fee and timeline estimation

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.